Mural Oncology
MURA
MURA was delisted on the 4th of December, 2025.
66 hedge funds and large institutions have $20.3M invested in Mural Oncology in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 8 increasing their positions, 21 reducing their positions, and 19 closing their positions.
44% more capital inflows, than outflows
Capital inflows: $10M | Capital outflows: $6.93M
1.05% less ownership
Funds ownership: 48.73% → 47.68% (-1%)
6% less funds holding
Funds holding: 70 → 66 (-4)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
62% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 21
79% less call options, than puts
Call options by funds: $548K | Put options by funds: $2.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.12M |
| 2 |
OrbiMed
New York
|
+$1.39M |
| 3 |
LMR Partners
London,
United Kingdom
|
+$1.22M |
| 4 |
Prosight Management
Dallas,
Texas
|
+$1.12M |
| 5 |
Diametric Capital
Boston,
Massachusetts
|
+$825K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$2.17M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
-$1.45M |
| 3 |
Solas Capital Management
Darien,
Connecticut
|
-$1.12M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$376K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$238K |
MURA Hedge Fund Activity: Q2 2025 in Review
66 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Mural Oncology (MURA) for Q2 2025, worth a combined $20.3M — up 92% from $10.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MURA and 17 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 8 added.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $3.12M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.17M sold.
- 66 institutional investors held Mural Oncology (MURA) as of Q2 2025, down from 70 in Q1 2025.
- Funds reported $20.3M of Mural Oncology stock for Q2 2025, up 92% quarter-over-quarter.
- 17 funds opened new Mural Oncology positions in Q2 2025 and 19 closed out, a net change of -2 holders.
- The largest Mural Oncology buyer in Q2 2025 was Soleus Capital Management, an estimated $3.12M added.
- The largest Mural Oncology seller in Q2 2025 was Armistice Capital, an estimated $2.17M sold.
Based on aggregated 13F filings for Q2 2025.